Skip to content

Clinical Experience With RIST-Based Multimodality Therapy in Relapsed Ewing Sarcoma: A Descriptive Single-center Case Series.

Sep 2026 · Journal of pediatric hematology/oncology · 0 citations · 17 references
Medicine

Abstract

Background

Outcomes for relapsed Ewing sarcoma remain poor. The RIST regimen (rapamycin, irinotecan, dasatinib, temozolomide) provides a targeted biological alternative to standard salvage chemotherapy.

Methods

We report 3 patients treated with RIST for relapsed Ewing sarcoma.Results:One patient with measurable disease achieved an early partial response before progressing at 9 months. Two patients received RIST as post-local-therapy consolidation with no evidence of disease, maintaining disease control for 41 and 44 months. Toxicities were manageable and primarily hematologic, without treatment discontinuations.

Conclusion

Prolonged outpatient RIST administration is feasible, and its role as multimodality consolidation warrants further prospective evaluation.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.